Month: April 2021

news_6

Treadwell Announces Initiation of Patient Dosing in TWT-202, a Phase 1b/2 study of PLK4 Inhibitor, CFI-400945, in Patients with Leukemia

Initial data to be presented in late 2021 NEW YORK--(BUSINESS WIRE)--Treadwell Therapeutics, a clinical-stage biotechnology company developing novel, cross-modality medicines...